Pfizer Corporation

Other

Ark Interface Ii, Inc.

Brian Thomas O'Neill

Michael Aaron Brodney

Christopher Ryan Butler

Elizabeth Mary Beck

Lei Zhang

Erik Alphie LaChapelle

Jennifer Elizabeth Davoren

Bruce Nelsen Rogers

Jotham Wadsworth Coe

Christopher John O'Donnell

Gabriela Barreiro

Douglas Phillips

Patrick Robert Verhoest

Christopher John Helal

Harry R Howard, Jr

Thomas C O'Rourke

Anton F Fliri

Mark Allen Sanner

Rodney C Cook

William Stephen Faraci

Lawrence Albert Vincent

Stevin H Zorn

Xinjun J Hou

Robert C Friedmann

John W Lackey

Kuntay O Taner

Adam R Joyner

Peter Justin Mikochik

John Charles Murray

John Adams Lowe, Iii

Yuhpyng Liang Chen

Harry Ralph Howard

Terry J Rosen

Fumitaka Ito

Arthur A Nagel

Thomas Allen Chappie

Edward F Kleinman

Masami Nakane

Spiros Liras

Kunio Satake

Frank R Busch

John L LaMattina

John Michael Humphrey

Frederick J Walker

Harry A Watson, Jr

Karen Jean Coffman

Martin Patrick Allen

Douglas J Allen

Masaya Ikunaka

Susan Beth Sobolov-Jaynes

Richard S Lehner

Jianhua Huang

Romelia Del Carmen Salomon Ferrer

Steven P Synder

Eric Platt Arnold

Steven P Snyder

The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, wherein the variables R, R, R, Rand X are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

N-(2-(2-amino-6-substituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]oxazin-8a(8H)-YL)-thiazol-4-YL) amides

The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variables R, Rand Rare as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

N-[2-(2-amino-6,6-disubstituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-YL)-1,3-thiazol-4-YL] amides

The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variable Ris as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

2-amino-6-methy1-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides

N-(2-(2-amino-6-substituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]OXAZIN-8a(8H)-yl)-thiazol-4-yl) amides

N-[2-(2-amino-6,6-disubstituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl)-1,3-thiazol-4-yl]amides

2-amino 6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides

The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, 

N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides

2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds

The present invention provides compounds of formula I, wherein the variables R, R, Rand b are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds

The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, wherein the variables Rand Rare as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

[object Object]

The present invention provides compounds of Formula I, and the tautomers thereof, and the pharmaceutically acceptable salts of the compounds and tautomers, wherein the compounds have the structure wherein the variables R, R, R, Rand x are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variables Rand Rare as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds

Growing community of inventors

Haddam, CT, United States of America

Brian Thomas O'Neill